DEFICIENT NIFEDIPINE OXIDATION - A RARE INHERITED TRAIT ASSOCIATED WITH CYSTIC-FIBROSIS KINDREDS

被引：16

作者：

DALY, AK ^{[1
]}

SALH, BS ^{[1
]}

BILTON, D ^{[1
]}

ALLEN, J ^{[1
]}

KNIGHT, AD ^{[1
]}

WEBB, AK ^{[1
]}

BRAGANZA, JM ^{[1
]}

IDLE, JR ^{[1
]}

机构：

[1] UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PHARMACOL SCI,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,ENGLAND

来源：

PHARMACOGENETICS | 1992年 / 2卷 / 01期

关键词：

D O I：

10.1097/00008571-199202000-00004

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Previous studies have indicated that there is weak genetic linkage between the defective gene in cystic fibrosis (CFTR) and the gene encoding the nifedipine metabolizing enzyme P4503A4 which are both located on chromosome 7. To examine further this possible association, nifedipine metabolism was investigated in a group of 59 volunteers, and 17 adult cystic fibrosis patients and 37 of their relatives. In agreement with the majority of previous studies, the volunteer group showed a unimodal distribution of recoveries for the major metabolite M-II ranging from 33 to 78% excretion in 8 h. In the case of both the cystic fibrosis patients and their parents, the distribution of recoveries was shifted to the left with five out of 20 parents and three out of 11 unrelated cystic fibrosis patients showing recoveries below the range observed in the volunteer group. This poor metabolism appeared to be both reproducible and heritable and did not appear to be a consequence of mutations in the CFTR gene.

引用

页码：19 / 24

页数：6

共 25 条

[1]

Ahsan C.H., Renwick A.G., Macklin B., Challenor V.F., Waller D.G., George C.F., Ethnic differences in the pharmacokinetics of oral nifedipine, Br J Clin Pharmacol, 31, pp. 399-403, (1991)

[2]

Aoyama T., Yamano S., Waxman D.J., Lapenson D.P., Meyer U.A., Fischer V., Tyndale R., Inaba T., Kalow W., Gelboin H.V., Gonzalez F.J., Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver, J Biol Chem, 264, pp. 10388-10395, (1989)

[3]

Blin N., Stafford D.W., A general method for the isolation of high molecular weight DNA from eukaryotes, Nucl Acids Res, 3, pp. 2303-2308, (1976)

[4]

Breimer D.D., Schellens J., Soons P.A., Nifedipine: Variability in its kinetics and metabolism in man, Pharmac Ther, 44, pp. 445-454, (1989)

[5]

Brooks B.A., Mc Bride O.W., Dolphin C.T., Farrall M., Scambler P.J., Gonzalez F.J., Idle J.R., The gene CYP3 encoding P450PCNI (Nifedipine oxidase) is tightly linked to the gene C0L1A2 encoding collagen type I alpha on 7q21-q22.1, Am J Hum Genet, 43, pp. 280-284, (1988)

[6]

Cutting G.R., Kasch L.M., Rosenstein B.J., Zielenski J., Tsui L.-C., Antonarakis S.E., Kazazian H.H., A cluster of cystic fibrosis mutations in the first nucleotide fold of the cystic fibrosis conductance regulator protein, Nature, 346, pp. 366-368, (1990)

[7]

Frizzell R.A., Rechkemmer G., Shoemaker R.L., Altered regulation of airway epithelial cell chloride channels in cystic fibrosis, Science, 233, pp. 558-560, (1986)

[8]

Gonzalez F.J., Schmid B.J., Umeno M., Mc Bride O.W., Hardwick J.P., Meyer U.A., Gelboin H.V., Idle J.R., Human P450PCN1: Sequence, chromosomal localization and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase, DNA, 7, pp. 79-86, (1988)

[9]

Guengerich F.P., Oxidative cleavage of carboxylic esters by cytochrome P450, J Biol Chem, 262, pp. 8459-8462, (1987)

[10]

Guengerich F.P., Bocker R.H., Cytochrome P450-catalysed dehydrogenation of 1,4 dihydropyridines, J Biol Chem, 263, pp. 8168-8175, (1988)

← 1 2 3 →